➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: November 25, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,076,515

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,076,515 protect, and when does it expire?

Patent 8,076,515 protects XADAGO and is included in one NDA.

This patent has fifty-three patent family members in twenty-six countries.

Summary for Patent: 8,076,515
Title:Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.
Inventor(s): Barbanti; Elena (Cologno Monzese, IT), Caccia; Carla (Cardano Al Campo, IT), Salvati; Patricia (Arese, IT), Velardi; Francesco (Cameri, IT), Ruffilli; Tiziano (Vigliano Biellese, IT), Bogogna; Luigi (Vaprio D'Agogna, IT)
Assignee: Newron Pharmaceuticals S.p.A. (Bresso, IT)
Application Number:12/338,825
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Process;

Drugs Protected by US Patent 8,076,515

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mdd Us XADAGO safinamide mesylate TABLET;ORAL 207145-001 Mar 21, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Mdd Us XADAGO safinamide mesylate TABLET;ORAL 207145-002 Mar 21, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,076,515

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06012565Jun 19, 2006

International Family Members for US Patent 8,076,515

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 061510   Start Trial
Australia 2007263328   Start Trial
Brazil PI0712936   Start Trial
Canada 2653012   Start Trial
China 101472880   Start Trial
China 103284984   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.